CD79B Antibody (AT107-2): sc-59115

CD79B Antibody (AT107-2) is a rat monoclonal IgG1 antibody that detects CD79B in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). CD79B, also known as B29, plays a crucial role in the formation of the B cell antigen receptor complex by pairing with CD79A, which is essential for B cell activation and signaling. CD79B is primarily located in the plasma membrane of B cells, where CD79B associates with membrane immunoglobulins like IgM and IgD, facilitating their surface expression and enabling effective antigen presentation. CD79B′s location is integral to the initiation of B cell responses to antigens, ultimately influencing the adaptive immune response. CD79B′s cytoplasmic tail contains an immuno-receptor tyrosine-based activation motif (ITAM), which is vital for recruiting and activating tyrosine kinases, thereby triggering downstream signaling pathways that lead to B cell proliferation and differentiation. Anti-CD79B antibody (AT107-2) serves as an invaluable tool for researchers studying B cell biology and immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD79B Antibody (AT107-2) References:

1. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.  |  Cabezudo, E., et al. 1999. Haematologica. 84: 413-8. PMID: 10329919
2. Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition.  |  Kouro, T., et al. 2001. Int Immunol. 13: 485-93. PMID: 11282988
3. Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line.  |  Minuzzo, S., et al. 2005. Br J Haematol. 130: 878-89. PMID: 16156858
4. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.  |  Zheng, B., et al. 2009. Mol Cancer Ther. 8: 2937-46. PMID: 19808977
5. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.  |  Jahn, L., et al. 2015. Blood. 125: 949-58. PMID: 25414443
6. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.  |  Frick, M., et al. 2018. Leuk Lymphoma. 59: 1260-1263. PMID: 28868954
7. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.  |  Schrader, AMR., et al. 2018. Blood. 131: 2086-2089. PMID: 29514783
8. Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.  |  Zhang, A., et al. 2024. Bioconjug Chem. 35: 140-146. PMID: 38265691
9. Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.  |  Esquinas, E., et al. 2024. J Immunother Cancer. 12: PMID: 39694704
10. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.  |  Astsaturov, IA., et al. 1996. Leukemia. 10: 769-73. PMID: 8656670

The preferred CD79B antibody is CD79B Antibody (B29/123): sc-53210.